Rezolute, Inc.

NASDAQ: RZLT · Healthcare · Biotechnology

PublicHQ Redwood City, CA · San MateoCIK 0001509261Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 63DQ —GM —SS 64

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$74.4M

Employees

as of 2026-08-12

Market cap

$444.9M

as of 2026-08-12

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$74.4M-$74.4M2025

Operating income-$79.9M-$79.9M2025

Total assets$175.5M$175.5M2025

Liabilities$13.4M$13.4M2025

Equity$162.1M$162.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Rezolute, Inc.’s financial profile?

Rezolute, Inc. earned -$74.4M in FY2025 net income.

Peers · Healthcare

Eikon Therapeutics, Inc. Common Stock——Kyverna Therapeutics, Inc.——Cabaletta Bio, Inc.——PureTech Health plc——Mobia Medical, Inc. Common Stock——Scribe Therapeutics Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$053D

Key facts

CEONevan Charles Elam

SectorHealthcare

IndustryBiotechnology

HeadquartersRedwood City, CA

ExchangeNASDAQ: RZLT

Employees68

IPO date2013-01-14

Latest filings

8-K2026-06-02 8-K2026-05-12 10-Q2026-05-12 8-K2026-05-04 8-K2026-03-24 8-K2026-02-12 10-Q2026-02-12 8-K2026-01-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.